Elite Pharmaceuticals Inc (ELTP)
0.5101
+0.01
(+1.75%)
USD |
OTCM |
Nov 04, 16:00
Elite Pharmaceuticals Enterprise Value: 534.85M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 534.85M |
| October 31, 2024 | 472.51M |
| October 30, 2024 | 463.97M |
| October 29, 2024 | 544.09M |
| October 28, 2024 | 607.11M |
| October 25, 2024 | 576.24M |
| October 24, 2024 | 614.05M |
| October 23, 2024 | 501.57M |
| October 22, 2024 | 640.23M |
| October 21, 2024 | 752.40M |
| October 18, 2024 | 624.21M |
| October 17, 2024 | 533.40M |
| October 16, 2024 | 517.38M |
| October 15, 2024 | 469.95M |
| October 14, 2024 | 445.81M |
| October 11, 2024 | 463.65M |
| October 10, 2024 | 433.41M |
| October 09, 2024 | 426.47M |
| October 08, 2024 | 430.10M |
| October 07, 2024 | 424.97M |
| October 04, 2024 | 417.71M |
| October 03, 2024 | 416.00M |
| October 02, 2024 | 447.67M |
| October 01, 2024 | 413.65M |
| September 30, 2024 | 413.76M |
| Date | Value |
|---|---|
| September 27, 2024 | 415.89M |
| September 26, 2024 | 414.77M |
| September 25, 2024 | 413.76M |
| September 24, 2024 | 403.72M |
| September 23, 2024 | 399.28M |
| September 20, 2024 | 397.71M |
| September 19, 2024 | 414.72M |
| September 18, 2024 | 413.22M |
| September 17, 2024 | 407.90M |
| September 16, 2024 | 415.68M |
| September 13, 2024 | 383.95M |
| September 12, 2024 | 428.71M |
| September 11, 2024 | 418.99M |
| September 10, 2024 | 378.29M |
| September 09, 2024 | 362.37M |
| September 06, 2024 | 334.17M |
| September 05, 2024 | 320.07M |
| September 04, 2024 | 293.04M |
| September 03, 2024 | 276.46M |
| August 30, 2024 | 294.80M |
| August 29, 2024 | 297.32M |
| August 28, 2024 | 300.95M |
| August 27, 2024 | 269.54M |
| August 26, 2024 | 254.80M |
| August 23, 2024 | 213.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
25.44M
Minimum
Mar 31 2023
752.40M
Maximum
Oct 21 2024
87.23M
Average
57.38M
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.36B |
| BioCardia Inc | 3.655M |
| Zevra Therapeutics Inc | 451.06M |
| Verrica Pharmaceuticals Inc | 76.10M |
| Terns Pharmaceuticals Inc | 263.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.6158M |
| Revenue (Quarterly) | 18.80M |
| Total Expenses (Quarterly) | 14.94M |
| EPS Diluted (Quarterly) | 0.0006 |
| Gross Profit Margin (Quarterly) | 45.07% |
| Profit Margin (Quarterly) | 3.27% |
| Earnings Yield | 2.21% |
| Operating Earnings Yield | 2.46% |
| Normalized Earnings Yield | 3.155 |